Herwig Lackner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Herwig Lackner has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Christian Urban
Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Division of Pediatric Hematology/Oncology, Graz, Austria
7 shared publications - Martin Benesch
Division of Paediatric Haematology/Oncology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, 8036 Graz, Austria
6 shared publications - Wolfgang Schwinger
Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Division of Pediatric Hematology/Oncology, Graz, Austria
5 shared publications - Petra Sovinz
Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, 8036 Graz, Austria
4 shared publications - Daniela Sperl
Division of Pediatric Hematology/Oncology Department of Pediatrics and Adolescent Medicine Medical University of Graz Graz Austria
3 shared publications - Volker Strenger
Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Austria
3 shared publications
Latest Publications
- 4 April 2017
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 229 (03) , 180-181
Central Hyperventilation in a Patient with Recurrent Acute Lymphoblastic Leukemia
Central hyperventilation (CH) is a respiratory pattern commonly observed in moribund patients due to advanced dysfunction of the respiratory centers in the brain stem. Hyperventilation which is not secondary to cardiorespiratory, metabolic or toxic disorders should lead the clinical suspicion to CH, which is defined as progressive tachypnea while awake and during sleep, accompanied by hypocapnia and respiratory alkalosis (Ledet et al., Neurology 2014; 82 (12): 1099–1100, Lange et al., J Neurol Neurosurg Psychiatry 1965; 28 (4): 317–319, Shahar et al., Pediatr Neurol 2004; 30 (4): 287–290). It is suspected to occur due to disruption of cortical inhibitory effects on the medullary respiratory centers, caused by various lesions of the cortex, the midbrain and the brainstem (Plum at al., AMA Arch Neurol Psychiatry 1959; 81 (5): 535–549, Gaviani et al., Neurology 2005; 64 (1): 166–167). CH has rarely been observed in conscious patients and in those cases it appeared mostly in the context of malignancies, involving the central nervous system (CNS). In adults CH seems to occur more frequently in association with cerebral lymphomas (Pauzner et al., Arch Neurol 1989; 46 (5): 510–512, Shibata et al., J Neurosurg 1992; 76 (4): 696–700). In children, data for this rare neurologic manifestation have not been reported in patients with hematologic malignancies. We describe a case of a child with an isolated CNS relapse of acute lymphoblastic leukemia (ALL) whose single presentation was CH.
- 4 April 2017
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 229 (03) , 180-181
Central Hyperventilation in a Patient with Recurrent Acute Lymphoblastic Leukemia
Central hyperventilation (CH) is a respiratory pattern commonly observed in moribund patients due to advanced dysfunction of the respiratory centers in the brain stem. Hyperventilation which is not secondary to cardiorespiratory, metabolic or toxic disorders should lead the clinical suspicion to CH, which is defined as progressive tachypnea while awake and during sleep, accompanied by hypocapnia and respiratory alkalosis (Ledet et al., Neurology 2014; 82 (12): 1099–1100, Lange et al., J Neurol Neurosurg Psychiatry 1965; 28 (4): 317–319, Shahar et al., Pediatr Neurol 2004; 30 (4): 287–290). It is suspected to occur due to disruption of cortical inhibitory effects on the medullary respiratory centers, caused by various lesions of the cortex, the midbrain and the brainstem (Plum at al., AMA Arch Neurol Psychiatry 1959; 81 (5): 535–549, Gaviani et al., Neurology 2005; 64 (1): 166–167). CH has rarely been observed in conscious patients and in those cases it appeared mostly in the context of malignancies, involving the central nervous system (CNS). In adults CH seems to occur more frequently in association with cerebral lymphomas (Pauzner et al., Arch Neurol 1989; 46 (5): 510–512, Shibata et al., J Neurosurg 1992; 76 (4): 696–700). In children, data for this rare neurologic manifestation have not been reported in patients with hematologic malignancies. We describe a case of a child with an isolated CNS relapse of acute lymphoblastic leukemia (ALL) whose single presentation was CH.
- Top Cited Papers
- 4 June 2015
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (12) , 1579-1584
Sirolimus for the treatment of children with various complicated vascular anomalies
Vascular anomalies include a heterogeneous group of disorders that are categorized as vascular tumors or vascular malformations. Treatment options include resection, embolization, laser therapy, and sclerotherapy or medical treatment such as propranolol, steroids, interferon, and cytostatic chemotherapy. Mammalian target of rapamycin seems to play a key role in the signal pathway of angiogenesis and subsequently in the development of vascular anomalies. Recently, the successful use of sirolimus has been reported in children with lymphatic malformations and kaposiform hemangioendotheliomas. We report on six patients with different vascular anomalies (kaposiform hemangioendothelioma n = 2, combined lymphatico-venous malformation n = 2, pulmonary lymphangiectasia n = 1, and orbital lymphatic malformation n = 1) who were treated with peroral sirolimus. Three of the children initially presented with a Kasabach-Merrit phenomenon. Median duration of treatment was 10 months; two children are still on treatment. Three children each achieved complete and partial remission. Kasabach-Merrit phenomenon resolved within 1 month in all patients. Treatment with sirolimus was tolerated well; only mild reversible leukopenia was observed. Conclusion: Sirolimus proved to be effective in children with complicated lymphatic or lymphatico-venous malformations and kaposiform hemangioendotheliomas. Treatment was tolerated well with acceptable side effects. The optimum length of treatment and possible long-term side effects have to be evaluated. What is Known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions. • Some patients are refractory to established treatment and/or are not available for local invasive procedures. What is New: • We reviewed the literature focusing treatment of vascular anomalies in children and adolescents. • Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors and malformations. What is Known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions. • Some patients are refractory to established treatment and/or are not available for local invasive procedures. What is New: • We reviewed the literature focusing treatment of vascular anomalies in children and adolescents. • Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors and malformations.
- 4 June 2015
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (12) , 1579-1584
Top Cited PapersSirolimus for the treatment of children with various complicated vascular anomalies
Vascular anomalies include a heterogeneous group of disorders that are categorized as vascular tumors or vascular malformations. Treatment options include resection, embolization, laser therapy, and sclerotherapy or medical treatment such as propranolol, steroids, interferon, and cytostatic chemotherapy. Mammalian target of rapamycin seems to play a key role in the signal pathway of angiogenesis and subsequently in the development of vascular anomalies. Recently, the successful use of sirolimus has been reported in children with lymphatic malformations and kaposiform hemangioendotheliomas. We report on six patients with different vascular anomalies (kaposiform hemangioendothelioma n = 2, combined lymphatico-venous malformation n = 2, pulmonary lymphangiectasia n = 1, and orbital lymphatic malformation n = 1) who were treated with peroral sirolimus. Three of the children initially presented with a Kasabach-Merrit phenomenon. Median duration of treatment was 10 months; two children are still on treatment. Three children each achieved complete and partial remission. Kasabach-Merrit phenomenon resolved within 1 month in all patients. Treatment with sirolimus was tolerated well; only mild reversible leukopenia was observed. Conclusion: Sirolimus proved to be effective in children with complicated lymphatic or lymphatico-venous malformations and kaposiform hemangioendotheliomas. Treatment was tolerated well with acceptable side effects. The optimum length of treatment and possible long-term side effects have to be evaluated. What is Known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions. • Some patients are refractory to established treatment and/or are not available for local invasive procedures. What is New: • We reviewed the literature focusing treatment of vascular anomalies in children and adolescents. • Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors and malformations. What is Known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions. • Some patients are refractory to established treatment and/or are not available for local invasive procedures. What is New: • We reviewed the literature focusing treatment of vascular anomalies in children and adolescents. • Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors and malformations.
- 12 August 2014
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 31 (8) , 723-730
Unrelated CD3/CD19-Depleted Peripheral Stem Cell Transplantation for Hurler Syndrome
For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice. One boy and one girl aged 20.5 and 22 months, respectively, with MPS1-H received a conditioning regimen consisting of thiotepa, fludarabine, treosulfan, and ATG. Grafts were peripheral blood stem cells from unrelated donors (10/12 and 11/11 matched), that were manipulated by CD3/CD19 depletion and contained 20.3 and 28.2 × 10(6) CD34+ cells/kg body weight, respectively. Both patients achieved stable hematopoietic engraftment and stable donor chimerism. Neither acute or chronic graft-versus-host disease (GVHD) nor other severe transplant-related complications occurred. At a follow-up of 48 and 37 months, both patients are alive and well with normal levels of α-L-iduronidase and have made major neurodevelopmental progress. Treosulfan-based conditioning offers the advantage of reduced toxicity; the use of unrelated CD3/CD19-depleted peripheral stem cell grafts allows transfusion of high CD34+ cell numbers together with a "tailored" number of CD3+ cells as well as engraftment facilitating cells in order to achieve rapid hematopoietic engraftment while reducing the risk of graft rejection and GVHD. This regimen might be an additional option when unrelated donor HSCT is considered for a patient with MPS1-H
- 12 August 2014
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 31 (8) , 723-730
Unrelated CD3/CD19-Depleted Peripheral Stem Cell Transplantation for Hurler Syndrome
For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice. One boy and one girl aged 20.5 and 22 months, respectively, with MPS1-H received a conditioning regimen consisting of thiotepa, fludarabine, treosulfan, and ATG. Grafts were peripheral blood stem cells from unrelated donors (10/12 and 11/11 matched), that were manipulated by CD3/CD19 depletion and contained 20.3 and 28.2 × 10(6) CD34+ cells/kg body weight, respectively. Both patients achieved stable hematopoietic engraftment and stable donor chimerism. Neither acute or chronic graft-versus-host disease (GVHD) nor other severe transplant-related complications occurred. At a follow-up of 48 and 37 months, both patients are alive and well with normal levels of α-L-iduronidase and have made major neurodevelopmental progress. Treosulfan-based conditioning offers the advantage of reduced toxicity; the use of unrelated CD3/CD19-depleted peripheral stem cell grafts allows transfusion of high CD34+ cell numbers together with a "tailored" number of CD3+ cells as well as engraftment facilitating cells in order to achieve rapid hematopoietic engraftment while reducing the risk of graft rejection and GVHD. This regimen might be an additional option when unrelated donor HSCT is considered for a patient with MPS1-H
- 1 June 2011
- Vol. 48 (6) , 481-3
Numb chin syndrome in acute lymphoblastic leukemia.
Numb chin syndrome is a sensory neuropathy of the inferior alveolar branch of the trigeminal nerve, characterized by unilateral numbness of the chin, the lower lip and the buccal and gingival mucosa. We report a girl with acute lymphoblastic leukemia of B-cell type who initially presented with numb chin syndrome resulting from skull base infiltration.
- 1 June 2011
- Vol. 48 (6) , 481-3
Numb chin syndrome in acute lymphoblastic leukemia.
Numb chin syndrome is a sensory neuropathy of the inferior alveolar branch of the trigeminal nerve, characterized by unilateral numbness of the chin, the lower lip and the buccal and gingival mucosa. We report a girl with acute lymphoblastic leukemia of B-cell type who initially presented with numb chin syndrome resulting from skull base infiltration.
- 1 May 2011
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 30 (5) , 440-442
THE SPECTRUM OF PARVOVIRUS B19 INFECTION IN A PEDIATRIC HEMATO-ONCOLOGIC WARD
Of 1059 children, 35 children with various hemato-oncologic diseases were diagnosed with parvovirus B19 infection. The clinical spectrum included 11 immunocompromised patients presenting with prolonged pancytopenia, 7 patients with delayed hematologic recovery after stem cell transplantation, 5 patients with parvovirus B19 as possible cause of severe aplastic anemia or myelodysplastic syndrome, and 12 children with hemolytic anemia and transient aplastic crisis.
- 1 May 2011
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 30 (5) , 440-442
THE SPECTRUM OF PARVOVIRUS B19 INFECTION IN A PEDIATRIC HEMATO-ONCOLOGIC WARD
Of 1059 children, 35 children with various hemato-oncologic diseases were diagnosed with parvovirus B19 infection. The clinical spectrum included 11 immunocompromised patients presenting with prolonged pancytopenia, 7 patients with delayed hematologic recovery after stem cell transplantation, 5 patients with parvovirus B19 as possible cause of severe aplastic anemia or myelodysplastic syndrome, and 12 children with hemolytic anemia and transient aplastic crisis.
- 1 January 2008
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 46 (5) , 487-490
Effective management of pulmonary aspergillosis invading the thoracic spine in a child with high risk ALL requiring allogeneic bone marrow transplantation
Due to unacceptably high mortality, invasive fungal infections (IFI) have long been considered a contraindication against allogeneic stem cell transplantation. Despite severe immunosuppression an 11-year-old girl requiring allogeneic bone marrow transplant (BMT) for relapsed acute lymphoblastic leukemia was cured of a concurrent invasive pulmonary aspergillosis. Treatment comprised combinations of liposomal amphotericin B, caspofungin and voriconazole with donor granulocyte transfusions. This therapeutic regimen, including the choice of reduced intensity conditioning (RIC), allowed the patient to receive an allogeneic BMT. In hematological remission the child later developed fatal chronic graft-versus-host disease. Combined antifungal treatment and granulocyte support allow for effective management of IFI even in allogeneic stem cell transplant recipients. However, short-term benefits of RIC may be outweighed by late complications.
- 1 January 2008
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 46 (5) , 487-490
Effective management of pulmonary aspergillosis invading the thoracic spine in a child with high risk ALL requiring allogeneic bone marrow transplantation
Due to unacceptably high mortality, invasive fungal infections (IFI) have long been considered a contraindication against allogeneic stem cell transplantation. Despite severe immunosuppression an 11-year-old girl requiring allogeneic bone marrow transplant (BMT) for relapsed acute lymphoblastic leukemia was cured of a concurrent invasive pulmonary aspergillosis. Treatment comprised combinations of liposomal amphotericin B, caspofungin and voriconazole with donor granulocyte transfusions. This therapeutic regimen, including the choice of reduced intensity conditioning (RIC), allowed the patient to receive an allogeneic BMT. In hematological remission the child later developed fatal chronic graft-versus-host disease. Combined antifungal treatment and granulocyte support allow for effective management of IFI even in allogeneic stem cell transplant recipients. However, short-term benefits of RIC may be outweighed by late complications.
- 1 January 2007
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 24 (3) , 209-219
CLINICAL, RADIOLOGICAL, AND PATHOLOGICAL FINDINGS IN FOUR CHILDREN WITH GASTROINTESTINAL STROMAL TUMORS OF THE STOMACH
The incidence of gastrointestinal stromal tumors (GISTs) in children is exceptionally low. However, during the last decade these tumors attracted increasing attention, because they were found to express the cell surface transmembrane receptor kit (CD117) that has tyrosine kinase activity. This tyrosine kinase can be semi-selectively inhibited by signal transduction inhibitors such as imatinib mesylate (Glivec), which is a competitive inhibitor of c-kit, c-abl, platelet-derived growth factor receptor-α (PDGFR-α) and PDGFR-β, and abl-related gene (arg). The authors present the clinical, radiographic, and pathological findings of 4 children who were diagnosed with gastric GIST. One of them had an incomplete Carney triad including GIST and mediastinal paraganglioma. All 4 patients presented with anemia and anemia-related symptoms and underwent total resection of the tumor. One patient received additional chemotherapy (in the pre-imatinib era) and 2 patients received a short course of imatinib mesylate. With a follow-up of 116, 55, 23, and 10 months all patients are alive in first complete continuous remission. In children and adolescents, particularly in female patients, GISTs should be included in the differential diagnosis of anemia secondary to gastrointestinal hemorrhage. Complete surgical resection is the mainstay of treatment for this tumor, with imatinib mesylate restricted to patients with advanced or metastatic tumors. Since late recurrences (up to 30 years following initial diagnosis) are reported, a life-long follow-up is mandatory in these patients.
- 1 January 2007
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 24 (3) , 209-219
CLINICAL, RADIOLOGICAL, AND PATHOLOGICAL FINDINGS IN FOUR CHILDREN WITH GASTROINTESTINAL STROMAL TUMORS OF THE STOMACH
The incidence of gastrointestinal stromal tumors (GISTs) in children is exceptionally low. However, during the last decade these tumors attracted increasing attention, because they were found to express the cell surface transmembrane receptor kit (CD117) that has tyrosine kinase activity. This tyrosine kinase can be semi-selectively inhibited by signal transduction inhibitors such as imatinib mesylate (Glivec), which is a competitive inhibitor of c-kit, c-abl, platelet-derived growth factor receptor-α (PDGFR-α) and PDGFR-β, and abl-related gene (arg). The authors present the clinical, radiographic, and pathological findings of 4 children who were diagnosed with gastric GIST. One of them had an incomplete Carney triad including GIST and mediastinal paraganglioma. All 4 patients presented with anemia and anemia-related symptoms and underwent total resection of the tumor. One patient received additional chemotherapy (in the pre-imatinib era) and 2 patients received a short course of imatinib mesylate. With a follow-up of 116, 55, 23, and 10 months all patients are alive in first complete continuous remission. In children and adolescents, particularly in female patients, GISTs should be included in the differential diagnosis of anemia secondary to gastrointestinal hemorrhage. Complete surgical resection is the mainstay of treatment for this tumor, with imatinib mesylate restricted to patients with advanced or metastatic tumors. Since late recurrences (up to 30 years following initial diagnosis) are reported, a life-long follow-up is mandatory in these patients.
- 13 March 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 49 (7) , 1012-1014
Clinical appearance of neuroblastoma 10 years after screening
A follow-up study was performed for children with previous repeated positive results by neuroblastoma mass screening and negative clinical results (30 out of 439,128 children screened in Austria between 1991 and 2003, median follow-up 113 months). Four children had continuously elevated urine catecholamines for more than 6 months. One of these patients was diagnosed with pelvic neuroblastoma and multiple metastases 10 years after the first positive screening result. In the light of a 'wait and see' strategy for localized neuroblastomas, our observation suggests that these patients should be further observed even after normalization of urine catecholamines.
- 13 March 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 49 (7) , 1012-1014
Clinical appearance of neuroblastoma 10 years after screening
A follow-up study was performed for children with previous repeated positive results by neuroblastoma mass screening and negative clinical results (30 out of 439,128 children screened in Austria between 1991 and 2003, median follow-up 113 months). Four children had continuously elevated urine catecholamines for more than 6 months. One of these patients was diagnosed with pelvic neuroblastoma and multiple metastases 10 years after the first positive screening result. In the light of a 'wait and see' strategy for localized neuroblastomas, our observation suggests that these patients should be further observed even after normalization of urine catecholamines.
- 1 July 1997
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 209 (04) , 235-242
The influence of maximum supportive care on dose compliance and survival
Background The administration of intensive, risk adapted multiagent chemotherapy has markedly improved the event-free survival in childhood acute lymphoblastic leukemia and Non-Hodgkin's lymphoma. Current treatment protocols may achieve complete remission rates of more than 95% and event-free survival rates of approximately 70% in non-B-acute lymphoblastic leukemia/non-B-Non-Hodgkin's lymphoma patients. Due to a higher proliferation rate and aggressiveness of B-cells treatment of B-acute lymphoblastic leukemia/ B-Non-Hodgkin's lymphoma must be more intensive, but can be shorter to attain similar event-free survival rates. Methods Between 1984 and 1993 79 primarily admitted patients up to 18 years of age (range 0.6-17.9 years) received therapy according to the treatment protocols ALL A 84, ALL 86, NHL 86, ALL 90 and NHL 90 of the Berlin-Frankfurt-Münster Study Group. Intensive phases of treatment were given on an inpatient basis with maximum supportive care in order to achieve the prescribed doses. Results Median follow-up time from diagnosis is now 8 years (range 40 to 157 months) with a probability of event-free survival of 92% for the entire group. Conclusion Multiagent chemotherapy tailored to the individual risk profile of each patient but given in the prescribed dose is currently the mainstay to achieve high complete remission rates with the aim to cure most acute lymphoblastic leukemia/Non-Hodgkin's lymphoma patients. The administration of intensive supportive care is important for the achievement of complete drug dosage and for the reduction of therapy-related toxicity. Hintergrund Durch den Einsatz intensiver risikoadaptierter Polychemotherapie hat sich das ereignisfreie Überleben bei akuten lymphoblastischen Leukämien und Non-Hodgkin-Lymphomen im Kindesalter deutlich verbessern lassen. Derzeitige Behandlungsprotokolle erzielen komplette Remissionen in mehr als 95% und ereignisfreies Überleben in ungefähr 70% der Patienten mit akuter Non-B-lymphoblastischer Leukämie und Non-B-Non-Hodgkin-Lymphom. Eine intensivere, jedoch kürzere Therapie ist aufgrund der höheren Proli ferationsrate maligner B-Zellen bei der Behandlung der aggressiveren akuten B-lymphoblastischen Leukämie und des B-Non-Hodgkin-Lymphom's nötig, um ähnliche Therapieergebnisse zu erzielen. Patienten und Methoden Zwischen 1984 und 1993 wurden 79 erstaufgenommene Patienten bis zum 18. Lebensjahr (0,6-17,9 Jahre) entsprechend den Behandlungsprotokollen ALL A 84, ALL 86, NHL 86, ALL 90 und NHL 90 der BFM-Arbeitsgruppe behandelt. Die Patienten wurden während intensiver Behandlungsphasen stationär aufgenommen und erhielten bei maximaler supportiver Therapie genau die vom Protokoll vorgeschriebenen Medikamentendosen. Ergebnisse Die mediane Nachbeobachtungszeit beträgt seit Diagnosestellung 8 Jahre (range 40-157 Monate) mit einer Wahrscheinlichkeit des ereignisfreien Überlebens von 92%. Schlußfolgerung Die dem individuellen Risikoprofil des Patienten angepaßte und ohne Dosisreduktion verabreichte zytostatische Polychemotherapie ist derzeit immer noch der wesentlichste Faktor, um hohe komplette Remissionsraten mit dem Ziel der Heilung zu erreichen. Der begleitende Einsatz intensiver supportiver Therapie ist unerläßlich, um die vorgeschriebene Behandlungsdosis bei gleichzeitiger Reduktion therapiebedingter Nebenwirkungen zu gewährleisten.
- 1 July 1997
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 209 (04) , 235-242
The influence of maximum supportive care on dose compliance and survival
Background The administration of intensive, risk adapted multiagent chemotherapy has markedly improved the event-free survival in childhood acute lymphoblastic leukemia and Non-Hodgkin's lymphoma. Current treatment protocols may achieve complete remission rates of more than 95% and event-free survival rates of approximately 70% in non-B-acute lymphoblastic leukemia/non-B-Non-Hodgkin's lymphoma patients. Due to a higher proliferation rate and aggressiveness of B-cells treatment of B-acute lymphoblastic leukemia/ B-Non-Hodgkin's lymphoma must be more intensive, but can be shorter to attain similar event-free survival rates. Methods Between 1984 and 1993 79 primarily admitted patients up to 18 years of age (range 0.6-17.9 years) received therapy according to the treatment protocols ALL A 84, ALL 86, NHL 86, ALL 90 and NHL 90 of the Berlin-Frankfurt-Münster Study Group. Intensive phases of treatment were given on an inpatient basis with maximum supportive care in order to achieve the prescribed doses. Results Median follow-up time from diagnosis is now 8 years (range 40 to 157 months) with a probability of event-free survival of 92% for the entire group. Conclusion Multiagent chemotherapy tailored to the individual risk profile of each patient but given in the prescribed dose is currently the mainstay to achieve high complete remission rates with the aim to cure most acute lymphoblastic leukemia/Non-Hodgkin's lymphoma patients. The administration of intensive supportive care is important for the achievement of complete drug dosage and for the reduction of therapy-related toxicity. Hintergrund Durch den Einsatz intensiver risikoadaptierter Polychemotherapie hat sich das ereignisfreie Überleben bei akuten lymphoblastischen Leukämien und Non-Hodgkin-Lymphomen im Kindesalter deutlich verbessern lassen. Derzeitige Behandlungsprotokolle erzielen komplette Remissionen in mehr als 95% und ereignisfreies Überleben in ungefähr 70% der Patienten mit akuter Non-B-lymphoblastischer Leukämie und Non-B-Non-Hodgkin-Lymphom. Eine intensivere, jedoch kürzere Therapie ist aufgrund der höheren Proli ferationsrate maligner B-Zellen bei der Behandlung der aggressiveren akuten B-lymphoblastischen Leukämie und des B-Non-Hodgkin-Lymphom's nötig, um ähnliche Therapieergebnisse zu erzielen. Patienten und Methoden Zwischen 1984 und 1993 wurden 79 erstaufgenommene Patienten bis zum 18. Lebensjahr (0,6-17,9 Jahre) entsprechend den Behandlungsprotokollen ALL A 84, ALL 86, NHL 86, ALL 90 und NHL 90 der BFM-Arbeitsgruppe behandelt. Die Patienten wurden während intensiver Behandlungsphasen stationär aufgenommen und erhielten bei maximaler supportiver Therapie genau die vom Protokoll vorgeschriebenen Medikamentendosen. Ergebnisse Die mediane Nachbeobachtungszeit beträgt seit Diagnosestellung 8 Jahre (range 40-157 Monate) mit einer Wahrscheinlichkeit des ereignisfreien Überlebens von 92%. Schlußfolgerung Die dem individuellen Risikoprofil des Patienten angepaßte und ohne Dosisreduktion verabreichte zytostatische Polychemotherapie ist derzeit immer noch der wesentlichste Faktor, um hohe komplette Remissionsraten mit dem Ziel der Heilung zu erreichen. Der begleitende Einsatz intensiver supportiver Therapie ist unerläßlich, um die vorgeschriebene Behandlungsdosis bei gleichzeitiger Reduktion therapiebedingter Nebenwirkungen zu gewährleisten.